Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05RXW
|
||||
Former ID |
DIB010037
|
||||
Drug Name |
LAS-41002
|
||||
Synonyms |
Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall
|
||||
Indication | Eczema [ICD10:L20-L30] | Phase 2 | [1] | ||
Company |
Almirall Prodesfarma SA
|
||||
Target and Pathway | |||||
Target(s) | Glucocorticoid receptor | Target Info | Modulator | [2] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
NetPath Pathway | IL2 Signaling Pathway | ||||
TCR Signaling Pathway | |||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
FOXA2 and FOXA3 transcription factor networks | |||||
Glucocorticoid receptor regulatory network | |||||
Regulation of Androgen receptor activity | |||||
AP-1 transcription factor network | |||||
Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | ||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
SIDS Susceptibility Pathways | |||||
Nuclear Receptors Meta-Pathway | |||||
Endoderm Differentiation | |||||
Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||||
Adipogenesis | |||||
Circadian Clock | |||||
Nuclear Receptors | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01119313) Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema. U.S. National Institutes of Health. | ||||
REF 2 | Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Dermatol Res Pract. 2012; 2012: 923134. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.